BR112018011892A2 - agonistas seletivos do receptor de glucagon compreendendo uma porção quelante para propósitos de produção de imagem - Google Patents

agonistas seletivos do receptor de glucagon compreendendo uma porção quelante para propósitos de produção de imagem

Info

Publication number
BR112018011892A2
BR112018011892A2 BR112018011892-3A BR112018011892A BR112018011892A2 BR 112018011892 A2 BR112018011892 A2 BR 112018011892A2 BR 112018011892 A BR112018011892 A BR 112018011892A BR 112018011892 A2 BR112018011892 A2 BR 112018011892A2
Authority
BR
Brazil
Prior art keywords
glucagon receptor
chelating moiety
receptor agonists
imaging purposes
selective glucagon
Prior art date
Application number
BR112018011892-3A
Other languages
English (en)
Inventor
Haack Torsten
Plettenburg Oliver
Evers Andreas
Wagner Michael
Bossart Martin
Bertrand Romain
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of BR112018011892A2 publication Critical patent/BR112018011892A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente invenção refere-se aos análogos do peptídeo exendina-4 que ligam e ativam seletivamente o receptor de glucagon e compreendem uma porção quelante capaz de ligar um íon de metal, e ao seu uso, por exemplo, na produção de imagem por pet.
BR112018011892-3A 2015-12-14 2016-12-12 agonistas seletivos do receptor de glucagon compreendendo uma porção quelante para propósitos de produção de imagem BR112018011892A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15307000 2015-12-14
EP15307000.8 2015-12-14
PCT/EP2016/080553 WO2017102613A1 (en) 2015-12-14 2016-12-12 Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes

Publications (1)

Publication Number Publication Date
BR112018011892A2 true BR112018011892A2 (pt) 2018-12-04

Family

ID=55129466

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011892-3A BR112018011892A2 (pt) 2015-12-14 2016-12-12 agonistas seletivos do receptor de glucagon compreendendo uma porção quelante para propósitos de produção de imagem

Country Status (21)

Country Link
US (1) US11046743B2 (pt)
EP (1) EP3389697B1 (pt)
JP (1) JP6986516B2 (pt)
KR (1) KR20180086270A (pt)
CN (1) CN108697767B (pt)
AU (1) AU2016372245B2 (pt)
BR (1) BR112018011892A2 (pt)
CA (1) CA3008052C (pt)
DK (1) DK3389697T3 (pt)
ES (1) ES2846023T3 (pt)
HR (1) HRP20210073T1 (pt)
HU (1) HUE053079T2 (pt)
IL (1) IL259961A (pt)
LT (1) LT3389697T (pt)
MX (1) MX2018007323A (pt)
PL (1) PL3389697T3 (pt)
PT (1) PT3389697T (pt)
RU (1) RU2018125958A (pt)
SG (1) SG11201804993RA (pt)
SI (1) SI3389697T1 (pt)
WO (1) WO2017102613A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004043153B4 (de) 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
PE20061448A1 (es) 2005-05-26 2006-12-17 Bristol Myers Squibb Co Compuestos polipeptidos como moduladores del peptido 1 similar al glucagon humano
WO2007139589A1 (en) * 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
UA116217C2 (uk) * 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
ES2653765T3 (es) 2012-12-21 2018-02-08 Sanofi Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
US9932381B2 (en) * 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists

Also Published As

Publication number Publication date
LT3389697T (lt) 2021-02-10
WO2017102613A1 (en) 2017-06-22
HRP20210073T1 (hr) 2021-04-30
JP6986516B2 (ja) 2021-12-22
US11046743B2 (en) 2021-06-29
SI3389697T1 (sl) 2021-02-26
MX2018007323A (es) 2019-01-10
EP3389697B1 (en) 2020-12-16
KR20180086270A (ko) 2018-07-30
DK3389697T3 (da) 2021-01-11
PL3389697T3 (pl) 2021-04-19
HUE053079T2 (hu) 2021-06-28
EP3389697A1 (en) 2018-10-24
AU2016372245A1 (en) 2018-07-26
CN108697767A (zh) 2018-10-23
SG11201804993RA (en) 2018-07-30
AU2016372245B2 (en) 2020-07-16
CN108697767B (zh) 2022-04-15
JP2019508480A (ja) 2019-03-28
CA3008052A1 (en) 2017-06-22
CA3008052C (en) 2024-01-02
RU2018125958A (ru) 2020-01-20
RU2018125958A3 (pt) 2020-06-09
ES2846023T3 (es) 2021-07-28
PT3389697T (pt) 2021-01-22
US20200262885A1 (en) 2020-08-20
IL259961A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
CL2018000920A1 (es) Conjugados de anticuerpos que comprenden agonistas de receptor similares
IL254088A0 (en) Cure using cd137 binding antibody
CO2018004743A2 (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
CL2017002401A1 (es) Anticuerpos contra icos
BR112018007225A2 (pt) agonistas do receptor de glucagon
BR112018013530A2 (pt) ?peptídeo isolado, polinucleotídeo e composição farmacêutica?
HK1249527A1 (zh) Cd137特異性的蛋白
BR112019006194A2 (pt) composições que compreendem um ligante de ligação ao receptor de canabinóides
IL266984A (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
CL2017003389A1 (es) Composiciones de pienso para animales y usos de las mismas.
UY37141A (es) Anticuerpos dirigidos a tigit
BR112017017672A2 (pt) material suplementar para uso na alimentação de animais domésticos.
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
BR112017024138A2 (pt) guia de onda que tem um material não condutor e métodos para uso com o mesmo.
IL248013A0 (en) glp-1/glucagon agonists derived from exendin-4
SV2018005643A (es) Composiciones de insulina de rapida accion
BR112017027567A2 (pt) proteínas de fusão para inibir a angiogênese
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
EP3745307C0 (en) CARD PRINTING MECHANISM WITH CARD RETURN PATH
UY36678A (es) Anticuerpos anti-fcrn.
CL2018000946A1 (es) Proteínas de unión a antigeno que activan el receptor de leptina
BR112018011008A2 (pt) agonistas de cnp de liberação controlada com ligação a npr-c baixa
CO2020006453A2 (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
CR20170518A (es) Neutralización del virus chikungunya mediada por anticuerpos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements